Serum Paraoxonase-1 Activity in Prostate Cancer Patients Treated with Brachytherapy as a Measure of Irradiation Efficacy.
Dorota M Olszewska-SłoninaMilosz JasinskiPublished in: Antioxidants (Basel, Switzerland) (2023)
We investigated changes in the activity of antioxidant paraoxonase-1 (PON1) in patients with prostate cancer (PCa) undergoing radiotherapy (RT), as well as the relationship of the PON1 activity with the degree of PCa advancement. We included 84 men with PCa. Blood samples were obtained before irradiation and after the completion of RT. The control group was composed of 60 healthy men. There was no significant difference in the PON1 activity between the control group and patients pre-radiotherapy. Irradiation was associated with a significant decrease in the PON1 activity; thus, it could be a measure of the efficacy of RT. No significant correlations between the PON1 activity and Gleason score, prostate volume, BMI (body mass index), or adipose tissue thickness were found. However, there was a positive correlation between the PON1 activity and the PSA concentration in the group of PCa patients.
Keyphrases
- prostate cancer
- body mass index
- adipose tissue
- end stage renal disease
- radical prostatectomy
- early stage
- newly diagnosed
- chronic kidney disease
- radiation therapy
- radiation induced
- oxidative stress
- prognostic factors
- squamous cell carcinoma
- metabolic syndrome
- locally advanced
- peritoneal dialysis
- mass spectrometry
- patient reported outcomes
- high resolution
- high dose
- middle aged
- atomic force microscopy